Healios K.K. (TYO:4593)

Market Cap	42.01B +131.9%
Revenue (ttm)	97.00M -82.3%
Net Income	-3.89B
EPS	-38.41
Shares Out	115.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,483,500
Average Volume	4,692,370
Open	375.00
Previous Close	381.00
Day's Range	359.00 - 376.00
52-Week Range	194.00 - 747.00
Beta	1.51
RSI	51.76
Earnings Date	Feb 16, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 65
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4593

Financial Performance

In 2024, Healios K.K.'s revenue was 560.00 million, an increase of 362.81% compared to the previous year's 121.00 million. Losses were -4.24 billion, 10.8% more than in 2023.